GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cryo-Cell International Inc (AMEX:CCEL) » Definitions » Asset Turnover
中文

Cryo-Cell International (Cryo-Cell International) Asset Turnover

: 0.13 (As of Feb. 2024)
View and export this data going back to . Start your Free Trial

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Cryo-Cell International's Revenue for the three months ended in Feb. 2024 was $7.85 Mil. Cryo-Cell International's Total Assets for the quarter that ended in Feb. 2024 was $61.47 Mil. Therefore, Cryo-Cell International's Asset Turnover for the quarter that ended in Feb. 2024 was 0.13.

Asset Turnover is linked to ROE % through Du Pont Formula. Cryo-Cell International's annualized ROE % for the quarter that ended in Feb. 2024 was -20.82%. It is also linked to ROA % through Du Pont Formula. Cryo-Cell International's annualized ROA % for the quarter that ended in Feb. 2024 was 3.62%.


Cryo-Cell International Asset Turnover Historical Data

The historical data trend for Cryo-Cell International's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryo-Cell International Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 0.70 0.54 0.48 0.50

Cryo-Cell International Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.12 0.11 0.12 0.13

Competitive Comparison

For the Medical Care Facilities subindustry, Cryo-Cell International's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryo-Cell International Asset Turnover Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Cryo-Cell International's Asset Turnover falls into.



Cryo-Cell International Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Cryo-Cell International's Asset Turnover for the fiscal year that ended in Nov. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Nov. 2023 )/( (Total Assets (A: Nov. 2022 )+Total Assets (A: Nov. 2023 ))/ count )
=31.344/( (64.888+61.221)/ 2 )
=31.344/63.0545
=0.50

Cryo-Cell International's Asset Turnover for the quarter that ended in Feb. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Feb. 2024 )/( (Total Assets (Q: Nov. 2023 )+Total Assets (Q: Feb. 2024 ))/ count )
=7.852/( (61.221+61.711)/ 2 )
=7.852/61.466
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Cryo-Cell International  (AMEX:CCEL) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Cryo-Cell International's annulized ROE % for the quarter that ended in Feb. 2024 is

ROE %**(Q: Feb. 2024 )
=Net Income/Total Stockholders Equity
=2.224/-10.6845
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(2.224 / 31.408)*(31.408 / 61.466)*(61.466/ -10.6845)
=Net Margin %*Asset Turnover*Equity Multiplier
=7.08 %*0.511*-5.7528
=ROA %*Equity Multiplier
=3.62 %*-5.7528
=-20.82 %

Note: The Net Income data used here is four times the quarterly (Feb. 2024) net income data. The Revenue data used here is four times the quarterly (Feb. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Cryo-Cell International's annulized ROA % for the quarter that ended in Feb. 2024 is

ROA %(Q: Feb. 2024 )
=Net Income/Total Assets
=2.224/61.466
=(Net Income / Revenue)*(Revenue / Total Assets)
=(2.224 / 31.408)*(31.408 / 61.466)
=Net Margin %*Asset Turnover
=7.08 %*0.511
=3.62 %

Note: The Net Income data used here is four times the quarterly (Feb. 2024) net income data. The Revenue data used here is four times the quarterly (Feb. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Cryo-Cell International Asset Turnover Related Terms

Thank you for viewing the detailed overview of Cryo-Cell International's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryo-Cell International (Cryo-Cell International) Business Description

Traded in Other Exchanges
Address
700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of Prepacyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. All the business activity of the group functions through the United States and it derives revenue from processing and testing fees and storage fees charged each year for storage and through sales of the Prepacyte CB units.
Executives
David Portnoy director, officer: Co-Chief Executive Officer C/O FOCUS FINANCIAL GROUP, 61 HARBOUR WAY, BAL HARBOUR FL 33154
George Gaines director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Jonathan H. Wheeler director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Brian L. Sheehy director 415 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Mark L. Portnoy director, officer: Co-Chief Executive Officer 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Harold D. Berger director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Arthur Ellis director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Mary J Nyberg 10 percent owner 455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Cdmj Nyberg Family Trust 10 percent owner 455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Jill M Taymans officer: VP, Finance, CFO
Oleg Mikulinsky officer: Chief Information Officer 700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Anthony Atala director 700 BROOKER CREEK BOULEVARD, OLDSMAR FL 34677
Scott G Christian director
Sung Won Sohn director 700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Michael W. Cho director C/O IOWA STATE UNIVERSITY, 1600 S. 16TH STREET, AMES IA 50011-1250